Evaluation of Antifibrotic Activity of a Combination of a New Phytocomposition and Proanthocyanidins in Rats.

Background: Today, chronic liver diseases and pathologies that develop as their complications, such as LC or HCC, cause various socio-economic as well as medical problems, and therefore the elimination of fibrosis processes in the liver is an important urgent problem. In the event of complications such as LC and HCC, the process of LF acts as an immediate bridge. Which, in turn, is responsible for stopping changes in the liver at the stage of fibrosis. Aim: The focus of the investigations was on how the composition under investigation affected the early stages of liver fibrosis. The antifibrotic action of the substance under investigation was assessed primarily by focusing on the invariance of lowered markers or a decrease in fibrosis rates. Experimental Approach: All the studies conducted were carried out on rats, while severe chronic liver damage was caused by the introduction into the abdominal cavity according to a strict scheme of heliothrin, a substance with a hepatotoxic effect. The object of the study was a combination of heparin and yanatacin 1:1, the antifibrotic activity of which was studied in comparison with the popular drug Phosphogliv, widely used in medical practice. Key Results: In the conducted studies, it was noted that the combination of heparin and yantacin normalizes disorders caused by heliotrin in experimental animals, in particular, enzyme activity, cytokine levels, bile secretion and liver index. According to this activity, the comparative drug showed a clear advantage over phosphogliv. Conclusion: The studies show that the studied combination only prevents the transition of the fibrous process to the second or third stage, and therefore the search for drugs that can completely eliminate the stage of fibrosis in the liver has not lost its relevance.